Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives New Coverag

Research analysts at Bank of America began coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) in a research report issued on Monday, Briefing.com reports. The firm set a “buy” rating and a $29.00 price target on the biotechnology company’s stock. Bank of America‘s target price suggests a potential upside of 25.16% from […]

Related Keywords

Canada , United States , America , Christopher Richard Anzalone , Third Bancorp , Hedge Funds Weigh In On Arrowhead Pharmaceuticals , Citigroup , Royal Bank , Arrowhead Pharmaceuticals Inc , Star Investment Management Corp , Fifth Third Bancorp , Advisors Asset Management Inc , Morgan Stanley , Arrowhead Pharmaceuticals , Cantor Fitzgerald , Arrowhead Pharmaceuticals Trading , News Ratings For Arrowhead Pharmaceuticals Daily , Securities Exchange Commission , Analyst Recommendations For Arrowhead Pharmaceuticals , Get Free Report , Chardan Capital , Martin Javier San , Exchange Commission , Richard Anzalone , Asset Management , Star Investment Management , Arrowhead Pharmaceuticals Daily , Nasdaq Arwr , Arwr , Medical , Initiated Coverage , Bank Of America Co ,